This study establishes that GR exerts anti-tumor effects in CC HeLa cells by targeting CDK2, potentially via the novel CYP4A22-AS1/LINC00958–hsa-miR-133b–CDK2 regulatory axis. This evidence concerns the gene CYP4A22 and neoplasm.